CINECA IRIS Institutional Research Information System

SANGIOLO, Dario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.364
EU - Europa 3.121
AS - Asia 2.033
SA - Sud America 52
OC - Oceania 36
AF - Africa 32
Continente sconosciuto - Info sul continente non disponibili 9
Totale 10.647
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.028
CN - Cina 971
IT - Italia 943
DE - Germania 566
GB - Regno Unito 337
CA - Canada 316
IE - Irlanda 293
SG - Singapore 292
SE - Svezia 255
TR - Turchia 196
FR - Francia 152
FI - Finlandia 125
VN - Vietnam 109
JP - Giappone 100
UA - Ucraina 92
PL - Polonia 88
KR - Corea 86
IN - India 62
ID - Indonesia 54
ES - Italia 50
TW - Taiwan 48
HK - Hong Kong 37
NL - Olanda 32
AU - Australia 31
BE - Belgio 28
BR - Brasile 27
TH - Thailandia 24
NO - Norvegia 23
AT - Austria 22
RU - Federazione Russa 22
CH - Svizzera 20
IR - Iran 16
MX - Messico 16
PT - Portogallo 14
SN - Senegal 14
RO - Romania 11
SA - Arabia Saudita 11
AR - Argentina 10
GR - Grecia 9
HR - Croazia 9
IL - Israele 9
EU - Europa 7
CO - Colombia 6
BY - Bielorussia 5
EG - Egitto 5
HU - Ungheria 5
NZ - Nuova Zelanda 5
UZ - Uzbekistan 5
VE - Venezuela 5
CZ - Repubblica Ceca 4
DK - Danimarca 4
LT - Lituania 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
AM - Armenia 3
BA - Bosnia-Erzegovina 3
KE - Kenya 3
MK - Macedonia 3
NG - Nigeria 3
PA - Panama 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CL - Cile 2
MA - Marocco 2
MY - Malesia 2
PK - Pakistan 2
BT - Bhutan 1
GA - Gabon 1
LV - Lettonia 1
OM - Oman 1
PE - Perù 1
PH - Filippine 1
PR - Porto Rico 1
SI - Slovenia 1
UY - Uruguay 1
Totale 10.647
Salva come PNG Salva come JPEG
Città #
Chandler 523
Fairfield 406
Beijing 366
Houston 342
Munich 328
Dublin 291
Mcallen 278
Montréal 273
Ashburn 255
Singapore 214
Torino 201
Woodbridge 198
Ann Arbor 182
Seattle 169
Wilmington 146
Jacksonville 135
Turin 128
Nyköping 121
Cambridge 116
Shanghai 104
Pisa 100
Redwood City 94
New York 92
Medford 89
Dearborn 79
Villeurbanne 78
Princeton 77
Warsaw 70
Milan 61
Guangzhou 59
Dong Ket 55
Jakarta 53
Nanjing 51
Fremont 40
Taipei 37
Boston 36
San Diego 32
Hangzhou 30
Helsinki 24
Xian 24
Wuhan 23
Santa Clara 21
Washington 21
Boardman 20
Seoul 19
Los Angeles 18
Tokyo 17
Zhengzhou 17
Hebei 16
Hefei 16
Pune 16
Brussels 15
Chengdu 15
Rome 15
Changsha 14
Chicago 14
Dresden 14
Phoenix 14
Upper Marlboro 14
Istanbul 13
Silver Spring 13
Stavanger 13
Toronto 13
Vienna 13
Dallas 12
Kunming 12
Florence 11
Hong Kong 11
Norwalk 11
San Mateo 11
Berlin 10
Carrara 10
Changchun 10
Fuzhou 10
Jinan 10
Madrid 10
Paris 10
Bari 9
Columbus 9
Detroit 9
Falls Church 9
Lappeenranta 9
Mountain View 9
Mumbai 9
Tianjin 9
Ankara 8
Bangkok 8
Birmingham 8
Chongqing 8
Freiburg im Breisgau 8
Heidelberg 8
Ottawa 8
San Francisco 8
Buenos Aires 7
Central 7
Central District 7
Cuneo 7
Genoa 7
Izmir 7
Paredes 7
Totale 6.664
Salva come PNG Salva come JPEG
Nome #
Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. 1.387
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial 1.044
Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity? 495
Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy 429
Cytokine Induced Killer cells kill chemo-surviving melanoma cancer stem cells 315
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group 309
Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors. 244
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition 207
BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody 204
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models 197
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. 186
Post-Transplant Cyclophosphamide and Tacrolimus–Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 173
Adoptive immunotherapy against ovarian cancer 172
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma 157
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. 156
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 150
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells 149
Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives 146
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy 141
Activity of cytokine-induced killer cells against bone and soft tissue sarcoma. 137
Pazopanib and trametinib as a synergistic strategy against osteosarcoma: Preclinical activity and molecular insights 136
Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells. 133
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer 129
Abstract LB-366: Everolimus (EV) potentiates Sorafenib (SOR)activity in osteosarcoma (OS) preclinical models: a combination targeting the crosstalk between ERK1/2 and mTORC1/2 signaling pathways 121
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy 117
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 116
Next generation immune-checkpoints for cancer therapy 109
NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives 108
Recent advances in the development of breast cancer vaccines. 106
CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes 104
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. 103
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 100
Cytokine Induced Killer cells immunotherapy overcomes the resistance to MET tyrosine kinase inhibitors in nonsmall cell lung cancer 92
Recruitment, infiltration and cytotoxicity of hla-independent killer lymphocytes in three-dimensional melanoma models 89
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination 88
Treatment of metastatic melanoma: a multidisciplinary approach 88
Comparison of post-transplant events and outcomes in patients affected by haematological or solid malignancies undergone to a non-myeloablative allogeneic haematopoietic stem cell transplantation in progressive disease 86
Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers. 85
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells 84
Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells 84
Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies 84
Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich Syndrome gene 83
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours 83
Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks. 82
INCIDENCE OF HHV-6 AFTER NONMYELOABLATIVE HSCT IN REFRACTORY MALIGNANCIES 81
Adoptive immunotherapy against sarcomas. 79
Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation 75
Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective 75
Cytokine-induced killer cells as immunotherapy for solid tumors: current evidences and perspectives 71
Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD 71
Effective Activity of Cytokine Induced Killer Cells against Autologous Metastatic Melanoma including Cells with Stemness Features. 68
Cytokine-induced killer cells engineered with exogenous t-cell receptors directed against melanoma antigens: Enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition 67
Cytokine profiling of end stage cancer patients treated with immunotherapy 67
Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors. 66
Cytokine-Induced Killer (CIK) Cells from Colorectal Cancer Patients after Nonmyeloablative Hematopoietic Cell Transplantation: Tumor Killing Capacity and Alloreactivity across MHC Barriers 66
Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour 64
Alloreactivity and antitumor activity segregate within two distinct subsets of Cytokine-Induced Killer Cells: Implications for their infusion Across major HLA-barriers. 64
TCR gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naïve and memory T-cells without prior stimulation of endogenous TCR 61
Epha2 expression in bone sarcomas: Bioinformatic analyses and preclinical characterization in patient-derived models of osteosarcoma, ewing’s sarcoma and chondrosarcoma 59
Veliparib: a new therapeutic option in ovarian cancer? 56
Parp1 inhibitor and trabectedin combination does not increase tumor mutational burden in advanced sarcomas—a preclinical and translational study 54
Sequential Lentiviral Transduction Conferring Simultaneous Sensitivity to Ganciclovir and Resistance to Mycophenolate Mofetil 50
The Combination of Sorafenib and Everolimus abrogates mTORC-1 and mTORC2 up-regulation in preclinical models of Osteosarcoma. 47
Role of interferon in melanoma: old hopes and new perspectives 46
Outcome of allogeneic hematopoietic cell transplantation (HCT) for patients with severe aplastic anemkia (SAA) above the age of 40 years 46
Delving into PARP inhibition from bench to bedside and back 45
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer 44
Treating breast cancer with cell-based approaches: an overview 43
Oncoretroviral and Lentiviral Transduction of Donor T Cells to Facilitate Engraftment of Dog Leukocyte Antigen (DLA)-Haploidentical T-Cell-Depleted Marrow 42
Immunotherapy associated pulmonary toxicity: Biology behind clinical and radiological features 41
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies 41
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy 38
Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. 38
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST 37
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 37
Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. 34
Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study 31
Redirecting GVT after Allografting in Colorectal Cancer: Active Vaccination and Adoptive Immunotherapy 31
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers 30
Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect 29
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 28
Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19 26
Redirectedt cells in cancer therapy 25
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma 23
Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages 23
Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection 20
PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade 19
Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade 16
Cytokine induced killer cells as promising immunotherapy for solid tumors 14
Abstract 3998: Preclinical efficacy of a synthetic Notch-based combinatorial immunotherapy against colorectal cancer with HER2 amplification 13
Significance of TIM3 expression in cancer: From biology to the clinic 13
Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model 12
Epigenetic determinants in soft tissue sarcomas: molecular mechanisms and therapeutic targets 12
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification 11
Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective 9
Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy 7
MET Oncogene Targeting for Cancer Immunotherapy 5
Predictive and dynamic signature for anti-angiogenics in combination with PD-1 inhibitor in soft-tissue sarcoma: correlative studies linked to the IMMUNOSARC trial 2
Totale 10.980
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.521
article - articoli 0
book - libri 0
conference - conferenze 2.629
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.150
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.565 0 0 0 233 142 293 188 176 161 158 98 116
2020/20211.305 84 125 89 114 98 86 76 80 110 132 110 201
2021/20221.235 69 91 48 74 73 47 86 74 60 111 279 223
2022/20231.779 126 171 42 174 129 400 148 127 216 53 123 70
2023/20241.074 109 158 74 84 62 161 56 59 11 75 101 124
2024/2025426 57 161 156 52 0 0 0 0 0 0 0 0
Totale 10.980